Cargando…

PB2309: EVALUATION OF MORBIMORTALITY FACTORS OF PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Detalles Bibliográficos
Autores principales:	Pinto, M. I., Marques, B., Coelho, D., Martinho, P., Fidalgo, T., Carda, J. P., Sarmento Ribeiro, A. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431644/ http://dx.doi.org/10.1097/01.HS9.0000852064.37541.0c

Ejemplares similares

PB2304: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP): A SINGLE-CENTER EXPERIENCE
por: Kammoun, F., et al.
Publicado: (2022)

PB2634: USE OF N-ACETYLCYSTEINE THERAPY IN PATIENTS WITH RELAPSED REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Beyler, Ozlem, et al.
Publicado: (2023)

A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura
por: Goreshnik, Ashley, et al.
Publicado: (2020)

PB2658: IMMUNE THROMBOCYTOPENIC PURPURA IN ALBANIA
por: Grazhdani, Sara, et al.
Publicado: (2023)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

PB2627: THROMBOTIC THROMBOCYTOPENIC PURPURA, RELAPSE RELATED RISK FACTORS IN A CARE CENTER WITH LIMITED ACCESS TO ADAMTS13 LEVELS.
por: Goya, Santiago Riviello, et al.
Publicado: (2023)

Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Tozinameran: Acquired thrombotic thrombocytopenic purpura: case report
Publicado: (2022)

PB1857: NRF2 MODULATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A POSSIBLE NEW THERAPEUTIC APPROACH
por: Carda #, J. P., et al.
Publicado: (2022)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia
por: Pandey, Ramesh Kumar, et al.
Publicado: (2017)

Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Tozinameran: Acquired thrombotic thrombocytopenic purpura: 4 case reports
Publicado: (2021)

AZD-1222: Acquired thrombotic thrombocytopenic purpura: case report
Publicado: (2022)

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura()
por: Thomas, Mari R., et al.
Publicado: (2015)

PB1889: A CASE OF REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INDUCED IMMUNE THROMBOCYTOPENIC PURPURA SUCCESSFULLY TREATED WITH VENETOCLAX
por: Yavuz, B., et al.
Publicado: (2022)

Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011)

Dengue and Thrombotic Thrombocytopenic Purpura
por: Wiwanitkit, Viroj
Publicado: (2017)

Vaccination and Thrombotic Thrombocytopenic Purpura
por: Yavaşoğlu, İrfan
Publicado: (2020)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Hereditary Thrombotic Thrombocytopenic Purpura
por: Nusrat, Sanober, et al.
Publicado: (2023)

Thrombotic thrombocytopenic purpura secondary to Streptococcus
por: Morrin, M.J., et al.
Publicado: (2006)

PB2324: SAFE ADMINISTRATION OF SECOND DOSE OF MRNA COVID-19 VACCINE FOLLOWING DEVELOPMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA
por: Hajizadeh Barfejani, A., et al.
Publicado: (2022)

Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura
por: Little, Dustin J., et al.
Publicado: (2017)

Dramatic presentation of acquired thrombotic thrombocytopenic purpura associated with COVID-19
por: Capecchi, Marco, et al.
Publicado: (2020)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

The Long and Winding Road for New Treatments for Acquired Thrombotic Thrombocytopenic Purpura
por: Schutgens, Roger E.G.
Publicado: (2019)

Acquired thrombotic thrombocytopenic purpura following Pfizer COVID‐19 vaccination
por: Alislambouli, Mawaddah, et al.
Publicado: (2021)

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
por: de Oliveira Boechat, Tiago, et al.
Publicado: (2023)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
por: Syed, Umer, et al.
Publicado: (2018)

Novel therapies in thrombotic thrombocytopenic purpura
por: Masias, Camila, et al.
Publicado: (2017)

Thrombotic Thrombocytopenic Purpura Associated with Dermatomyositis
por: Malik, Zohra R, et al.
Publicado: (2018)

Cardiac implications of thrombotic thrombocytopenic purpura
por: Wiernek, Szymon L, et al.
Publicado: (2018)

Ticagrelor-associated thrombotic thrombocytopenic purpura
por: Doğan, Ali, et al.
Publicado: (2017)

Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura
por: Bukhari, Sumera, et al.
Publicado: (2020)

Hydroxychloroquine-Associated Thrombotic Thrombocytopenic Purpura
por: Arıkan, Fatma, et al.
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jl9na36shf9o1dru5il725tbro